氨己烯酸片(喜保宁)的效果好不好

Epilepsy, commonly known as "epilepsy" or "epilepsy", is a chronic disease in which brain nerves suddenly discharge abnormally, causing temporary brain dysfunction. According to China's latest epidemiological data, the overall prevalence of epilepsy in China is 7.0‰, the annual incidence rate is 28.8/100,000, and the prevalence of active epilepsy with seizures within 1 year is 4.6‰. (Vigabatrin) is currently an effective drug for the treatment of epilepsy. So is its therapeutic effect good?

Vigabatrin tablets (Vigabatrin) are analogs of γ-aminobutyric acid (GABA). They can specifically bind to GABA aminotransferase and irreversibly, leading to an increase in the concentration of GABA in the brain, thereby exerting anti-epileptic effects. This product is used as adjuvant therapy for the treatment of patients who are ineffective with other anti-epileptic drugs, especially those with partial seizures (mainly used to control complex partial seizures). Vigabatrin tablets (vigabatrin) can aggravate absence seizures or myoclonic seizures. Vigabatrin may also be used in infants with West syndrome (infantile spasms), which is generally unresponsive to conventional antiepileptic drugs. As an auxiliary therapeutic drug, this product can achieve better efficacy. When used alone, it is effective in the treatment of newly diagnosed patients.

The maximum dosage of vigabatrin tablets (Vigabatrin) for adults is 2-3 grams per day. It is appropriate to start taking it at 1g a day, and then according to the reaction after taking the medicine, if the reaction is good, it can be increased by 0.5g every week. Finally, the daily dosage is reached 2-3g. The maximum daily dosage should not exceed 3g.

A survey of aggregated data showed that as many as one-third of patients using vigabatrin tablets (Vigabatrin) had visual field defects. Men may be at greater risk than women. All patients should have an ophthalmological consultation including visual field examination before treatment with Vigabatrin.

Appropriate visual field testing should be performed before treatment and every 6 months during treatment, using standard static visual field static visual field (hymphrey or octopus) or dynamic visual field (goldmann). Static visual field is the preferred test method for detecting visual field defects caused by Xibaonin.

Electroretinography may be useful, but only in adults who cannot adapt to visual field testing. According to the available data the first oscillatory potential and the 30Hz flicker response are delayed and reduced beyond the normal range. This change has not occurred in patients without visual field defects who were treated with Vibatonin.

Patients and/or caregivers must be given a complete description of the frequency and impact of visual field defect development during treatment with Vigabatrin. Patients should be asked to report any new visual problems and symptoms related to visual field loss. If visual symptoms develop, the patient should be referred to an ophthalmologist.

Recommended related hot articles: /newsDetail/84693.html